A Mobile App for Mood, Routines and Medication in Severe Mental Illness
Tests the MoodSync app in adults with severe mental illness, alongside usual care.
Plain-language title generated from the registry record
Registry title: A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
Key facts
- Where
- Manama, BahrainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a severe mental illness who are clinically stable. It tests a mobile app for mood, daily routines and medication use, added to standard care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Bipolar I or II disorder, schizophrenia, schizoaffective disorder or major depressive disorder (DSM-5-TR), confirmed by the treating psychiatrist. Clinically stable: no psychiatric hospital admission in the previous 3 months.
- Earlier treatment
- Must be receiving care at a participating mental health service. No psychiatric hospital admission in the previous 3 months.
Main reasons for not taking part
- Acute psychiatric crisis at the time of recruitment
- Cannot give informed consent
- Severe cognitive impairment that prevents using the app
- No compatible mobile device, unless the project provides one
Read by machine on 9 November 2026.
Where in Bahrain
- Psychiatric Hospital, Government HospitalsManama, BahrainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Alexandria University
- Trial code
- NCT07879131
- Record updated
- 16 October 2026
- Original description
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning signs in adults with severe mental illness in Bahrain. The main question it aims to answer is: Does MoodSync plus standard care improve manic symptoms, medication adherence, practical and social functioning, and early warning signs more than standard care alone?Read full original descriptionShow less
Effectiveness of MoodSync: A Just-in-Time Dual Mobile Application for Mood Monitoring, Social Rhythm Regulation, Medication Adherence, and Relapse Prevention Among Patients With Severe Mental Illness: A Randomized Controlled Trial
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning signs in adults with severe mental illness in Bahrain. The main question it aims to answer is: Does MoodSync plus standard care improve manic symptoms, medication adherence, practical and social functioning, and early warning signs more than standard care alone?
Participants will be randomly assigned to MoodSync plus standard care or standard care alone. MoodSync participants will use the patient app for 12 weeks for daily mood check-ins, sleep and activity tracking with a wearable device, medication reminders, daily-routine (social rhythm) support and early warning-sign reporting. A nominated family caregiver may use the linked caregiver app. All participants continue standard care and complete questionnaires before and after the intervention period.
Research hypothesis:
* Patients who use MoodSync will show greater improvement in mood symptoms, medication adherence, practical and social functioning, and relapse-related outcomes than patients receiving standard care alone.
Inclusion: Adults aged 18 years or older; Diagnosis of a severe mental illness (bipolar I or II disorder, schizophrenia, schizoaffective disorder, or major depressive disorder) according to DSM-5-TR, confirmed by the treating psychiatrist; Clinically stable, defined as no psychiatric hospital admission in the previous 3 months; Receiving care at a participating mental health service; Able to use a smartphone application; Able to provide written informed consent.
Exclusion: Acute psychiatric crisis at the time of recruitment; Severe cognitive impairment preventing use of the application; Inability to provide informed consent; No access to a compatible mobile device, unless one is provided by the project; Family caregivers (intervention group, optional): adult family member nominated by the participant, who gives separate written informed consent.